HBM Holdings Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of antibody therapeutics focusing on immunology and oncology in Mainland China, the United States, Europe, and internationally. It develops the Harbour Mice Platform, which generates human monoclonal antibodies in two heavy and two light chain H2L2 and heavy chain formats. The company is developing Batoclimab (HBM9161), a human monoclonal antibody that selectively binds and inhibits the neonatal fragment crystallizable receptor for treating myasthenia gravis; Porustobart HBM4003, a human anti-CTLA-4 antibody against cytotoxic T-lymphocyte-associated antigen-4 for treating melanoma, colorectal cancer, hepatocellular carcinoma, and neuroendocrine neoplasm. It is developing HBM7020 for treating hepatocellular carcinoma and autoimmune diseases; HBM9378 for the treatment of asthma and chronic obstructive pulmonary disease; and HBM1020, HBM7022, HBM7008, HBM9027, HBM7004, and HBM9033 for treating solid tumors. The company has a strategic collaboration with Evinova to apply AI and digital technologies to enhance the efficiency of biologics development. The company was incorporated in 2016 and is based in Suzhou, the People's Republic of China.
Frequently asked questions
What sector does Hbm Holdings Ltd (2142) operate in?
Hbm Holdings Ltd belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Hbm Holdings Ltd (2142) current stock price?
As of the latest data, Hbm Holdings Ltd stock price is HK$14.19, with a previous close of HK$14.44. Hbm Holdings Ltd lost -HK$0.25 in the last trading session, representing a -1.73% loss.
What is Hbm Holdings Ltd (2142) current market capitalization?
Hbm Holdings Ltd market cap is approximately 11.85 billion.
What is Hbm Holdings Ltd (2142) EBITDA?
Hbm Holdings Ltd EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 69.31 million.
Does Hbm Holdings Ltd (2142) pay dividends?
No. Hbm Holdings Ltd does not pay a dividend.
What is Hbm Holdings Ltd (2142) beta (volatility) score?
Hbm Holdings Ltd has a beta of 1.368, suggesting it is more volatile than the market.
